Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
granisetron + metopimazine + prednisolone
- Development stage
- Unknown
- Lead developer
- Kyowa Kirin
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
A three-drug antiemetic combination used to prevent and treat chemotherapy-induced nausea and vomiting (CINV). This regimen combines three different mechanisms of action: granisetron (a serotonin 5-HT3 receptor antagonist), metopimazine (a dopamine D2 receptor antagonist), and prednisolone (a corticosteroid). It is particularly effective in patients who have previously experienced CINV or who were refractory to other antiemetic treatments.
02
Targets
HTR3A (5-hydroxytryptamine receptor 3A)GR (Glucocorticoid receptor)DRD2 (Dopamine D2 Receptor)
Beyond the preview
Go deeper on granisetron + metopimazine + prednisolone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on granisetron + metopimazine + prednisolone.